BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26446698)

  • 1. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
    Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
    J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
    Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
    J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
    JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.
    Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M
    Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
    Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
    Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
    Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
    Leu L; Baribeault D
    J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
    Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P
    J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mannitol on acute kidney injury induced by cisplatin.
    Bégin AM; Monfette ML; Boudrias-Dalle É; Lavallée E; Samouelian V; Soulières D; Chagnon M; Fournier MA; Letarte N; Adam JP
    Support Care Cancer; 2021 Apr; 29(4):2083-2091. PubMed ID: 32862356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
    Dana R; Kachhwaha VS
    Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study.
    El Hamamsy M; Kamal N; Bazan NS; El Haddad M
    Int J Clin Pharm; 2018 Dec; 40(6):1539-1547. PubMed ID: 30167970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
    van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
    BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
    Morgan KP; Buie LW; Savage SW
    Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
    Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
    Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
    Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
    Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
    Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
    Dimery IW; Legha SS
    J Clin Oncol; 1986 Nov; 4(11):1670-6. PubMed ID: 3095503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.